Ashfield Capital Partners LLC increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 246.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,272 shares of the life sciences company’s stock after buying an additional 25,805 shares during the quarter. Illumina comprises 1.5% of Ashfield Capital Partners LLC’s holdings, making the stock its 15th largest position. Ashfield Capital Partners LLC’s holdings in Illumina were worth $13,314,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in the stock. Daiwa Securities Group Inc. lifted its position in Illumina by 4.9% during the third quarter. Daiwa Securities Group Inc. now owns 6,902 shares of the life sciences company’s stock worth $2,533,000 after buying an additional 324 shares in the last quarter. Mission Wealth Management LP acquired a new stake in Illumina during the third quarter worth $4,632,000. Private Advisor Group LLC increased its stake in Illumina by 113.7% during the third quarter. Private Advisor Group LLC now owns 6,011 shares of the life sciences company’s stock worth $2,206,000 after acquiring an additional 3,198 shares during the last quarter. Chicago Equity Partners LLC acquired a new stake in Illumina during the third quarter worth $3,698,000. Finally, Engineers Gate Manager LP acquired a new stake in Illumina during the third quarter worth $6,774,000. Hedge funds and other institutional investors own 89.87% of the company’s stock.
In other news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Friday, August 10th. The stock was sold at an average price of $331.39, for a total value of $3,313,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Marc Stapley sold 1,000 shares of Illumina stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $352.05, for a total value of $352,050.00. Following the completion of the sale, the executive vice president now directly owns 8,816 shares of the company’s stock, valued at $3,103,672.80. The disclosure for this sale can be found here. Insiders sold 55,629 shares of company stock valued at $18,631,589 over the last ninety days. Insiders own 0.54% of the company’s stock.
ILMN has been the subject of several recent analyst reports. ValuEngine cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Canaccord Genuity reissued a “buy” rating and set a $340.00 target price (up previously from $330.00) on shares of Illumina in a research note on Friday, July 27th. Barclays raised their target price on Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 24th. Deutsche Bank raised their target price on Illumina from $280.00 to $330.00 and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Finally, BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $330.94.
Shares of NASDAQ ILMN opened at $328.10 on Monday. Illumina, Inc. has a twelve month low of $203.83 and a twelve month high of $372.61. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $48.23 billion, a PE ratio of 82.03, a PEG ratio of 2.43 and a beta of 1.07.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The business had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The company’s revenue was up 19.5% on a year-over-year basis. As a group, research analysts anticipate that Illumina, Inc. will post 5.75 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.